AUS
NZ
UK
CA
USA
IND
Highlights
- Arovella secures a $3 million R&D tax refund for FY2024, with more funding expected.
- Progress continues on ALA-101 as the company prepares for clinical trials.
- Arovella forms a Clinical Advisory Board ahead of a crucial FDA meeting.
Arovella Therapeutics Ltd (ASX:ALA), an Australian biotechnology company, has received a significant boost to its financial position with a $3 million refund through the Research and Development (R&D) Tax Incentive for the financial year 2024. This refund is part of Australia’s R&D incentive program, designed to encourage companies to pursue research initiatives. An additional $300,000 in funding is anticipated in the near future, stemming from costs covered under an advanced overseas finding. The refund came after Arovella lodged its income tax return, resulting in the substantial refund amount.
These additional funds further enhance Arovella’s ability to continue advancing its key asset, ALA-101, a next-generation "off-the-shelf" CAR-iNKT cell therapy. ALA-101 is designed to target CD19-positive B cell lymphomas and leukemias, marking it as a significant advancement in treating blood cancers. The company aims to progress this therapy into its first-in-human clinical trials, a critical step toward testing its effectiveness and safety.
Dr. Michael Baker, Arovella’s CEO and Managing Director, highlighted the importance of the R&D Tax Incentive program, noting that it provides essential support for companies like Arovella in advancing their research. The program allows eligible companies to receive cash refunds based on their R&D expenditure, further promoting innovation within the biotech sector. With these funds, Arovella plans to continue its progress towards clinical trials for ALA-101.
In preparation for these trials, Arovella has assembled a Clinical Advisory Board (CAB) consisting of leading clinical oncologists. This expert team will offer strategic guidance as the company prepares for a critical meeting with the US Food and Drug Administration (FDA). The board’s focus is on CD19-positive hematological malignancies, as the company works towards filing an Investigational New Drug (IND) application and starting its first-in-human Phase 1 clinical trial.
Arovella’s progress signals its commitment to advancing innovative therapies for blood cancers, supported by a strengthened financial position and expert clinical oversight as it navigates the regulatory process.
